go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Abbott Healthcare Products Limited

Abbott Healthcare Products Limited
2.1 Woodford Business Park, Santry, Dublin 9, Ireland
Telephone: +353 1 8468793
Fax: +353 1 8468701
Medical Information Direct Line: +44 (0)2380 467 000
Medical Information e-mail: medinfo.shl@abbott.com
Medical Information Facsimile: +44 (0)2380 467052


Summary of Product Characteristics last updated on medicines.ie: 17/02/2011
SPC Colofac 135mg Tablets

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipient(s)
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Colofac 135 mg tablets


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Mebeverine Hydrochloride 135 mg.

Excipients: also includes Lactose monohydrate 97.0 mg per tablet and Sucrose 79.0 mg per tablet.

For a full list of excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Coated tablet.

White, circular, sugar coated tablet.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For use in the management of irritable bowel syndrome, (particularly gastrointestinal spasm).


Go to top of the page
4.2 Posology and method of administration

Adults and children over 10 years:

One tablet three times a day preferably 20 minutes before meals.

After a period of several weeks when the desired effect has been obtained, the dosage may be gradually reduced.

Children and Infants:

Not recommended.


Go to top of the page
4.3 Contraindications

Use in patients with a known hypersensitivity to mebeverine.


Go to top of the page
4.4 Special warnings and precautions for use

Prior to treating patients with mebeverine, care should be taken to exclude organic disease of the bowel, particularly malignancy.

Patients with rare hereditary problems of galactose or fructose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

Although studies in animals have not shown any teratogenic effect which can be definitely attributed to mebeverine, the safety of Colofac in human pregnancy has not been established. On basic principles therefore, its use is not recommended.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Very rarely hypersensitivity reactions may occur, in particular, urticaria, angioedema, face oedema and exanthema/rash.


Go to top of the page
4.9 Overdose

On theoretical grounds, it may be predicted that CNS excitability will occur in cases of overdosage. No specific antidote is known; gastric lavage and symptomatic treatment is recommended.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract, relieving spasm without affecting normal gut motility.


Go to top of the page
5.2 Pharmacokinetic properties

Mebeverine is rapidly and completely absorbed after oral administration in the form of tablets or suspension. Mebeverine is not excreted as such, but metabolised completely. The first step in the metabolism is hydrolysis, leading to veratric acid and mebeverine alcohol. Both veratric acid and mebeverine alcohol are excreted into the urine, the latter partly as the corresponding carboxylic acid and partly as the demethylated carboxylic acid.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipient(s)

Lactose monohydrate

Starch (potato or maize)

Povidone

Talc

Magnesium stearate

Sucrose

Gelatin

Acacia

Carnauba wax


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

5 years.


Go to top of the page
6.4 Special precautions for storage

Do not store above 30°C.

Store in the original package.


Go to top of the page
6.5 Nature and contents of container

AL/PVC blisters in boxes containing 4 (physician's sample) or 100 tablets.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Abbott Healthcare products Limited

Mansbridge Road

West End

Southampton

SO18 3JD

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 108/14/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 07 February 1983

Date of last renewal: 07 February 2008


Go to top of the page
10. DATE OF REVISION OF THE TEXT

February 2011



Link to this document from your website:
http://www.medicines.ie/medicine/10082/SPC/Colofac+135mg+Tablets/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Legal Categories

 
   Product subject to medical
prescription which may not
be renewed (A)
   Product subject to medical
prescription which may
be renewed (B)
   Product subject to
restricted prescription
(C)
   Supply through
general sale
   Supply through
pharmacy only

Active Ingredients

 
   Mebeverine Hydochloride

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo